Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
ALX Oncology Holdings's operating assets for the quarter that ended in Jun. 2026 was $7.17 Mil. ALX Oncology Holdings's operating liabilities for the quarter that ended in Jun. 2026 was $14.66 Mil. ALX Oncology Holdings's Total Assets for the quarter that ended in Mar. 2026 was $178.33 Mil. Therefore, ALX Oncology Holdings's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2026 was -0.04.
ALX Oncology Holdings Scaled Net Operating Assets Related Terms
ALX Oncology Holdings Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for ALX Oncology Holdings's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALX Oncology Holdings Scaled Net Operating Assets Chart
ALXO vs CYDY, BCYC, ELDN: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, ALX Oncology Holdings's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -0.04 mean?
ALX Oncology Holdings (ALXO) has a Scaled Net Operating Assets of -0.04 as of Jun. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on ALX Oncology Holdings and its competitors.
Is ALX Oncology Holdings' Scaled Net Operating Assets too high?
ALX Oncology Holdings' current Scaled Net Operating Assets is -0.04. Overall, ALX Oncology Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does ALX Oncology Holdings' Scaled Net Operating Assets compare to CYDY and BCYC?
ALX Oncology Holdings' Scaled Net Operating Assets of -0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on ALX Oncology Holdings and its competitors. ALX Oncology Holdings's current Scaled Net Operating Assets is -0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALX Oncology Holdings stock overvalued right now?
ALX Oncology Holdings (ALXO) has a current Scaled Net Operating Assets of -0.04. The current Scaled Net Operating Assets is -0.04. ALX Oncology Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For ALX Oncology Holdings (ALXO), the current Scaled Net Operating Assets is -0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
31GF Score
Get the complete analysis for ALXO
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALXO has been successfully added to your 
